Research programme: antitussive therapeutics - Chiesi USA
Alternative Names: CRTX 069; CRTX 072; CRTX 074Latest Information Update: 29 Mar 2012
At a glance
- Originator Cornerstone Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis; Cough
Most Recent Events
- 31 Dec 2011 Discontinued - Preclinical for Allergic rhinitis in USA (PO)
- 31 Dec 2011 Discontinued - Preclinical for Cough in USA (PO)
- 31 Dec 2008 Preclinical trials in Allergic rhinitis in USA (PO)